Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5022,622.71.16%H 22,757.95 · L 22,558.95as of 14 Oct, 3:31 PM IST|Sensex72,781.891.19%H 73,195.26 · L 72,578.75as of 14 Oct, 3:32 PM IST|Bank Nifty55,3160.72%H 55,644.7 · L 55,168.2as of 14 Oct, 3:31 PM IST|USD / INR₹95.140%H ₹95.27 · L ₹94.74as of 3:05 AM IST|Gold Intl (10g)₹1,27,286.671.3%H ₹1,27,482.43 · L ₹1,26,050.9upd. 6:26 AM IST|Silver Intl (1kg)₹1,71,890.380.57%H ₹1,72,272.73 · L ₹1,70,131.55upd. 6:26 AM IST|Crude WTI₹8,991.680.61%H ₹9,067.79 · L ₹8,982.17upd. 6:26 AM IST|Bitcoin₹78,55,7000.75%H ₹78,85,167.77 · L ₹78,26,232.23as of 14 Oct, 6:46 PM IST|Ethereum₹2,35,0291.22%H ₹2,36,466.39 · L ₹2,33,591.61as of 14 Oct, 6:46 PM IST|Nifty 5022,622.71.16%H 22,757.95 · L 22,558.95as of 14 Oct, 3:31 PM IST|Sensex72,781.891.19%H 73,195.26 · L 72,578.75as of 14 Oct, 3:32 PM IST|Bank Nifty55,3160.72%H 55,644.7 · L 55,168.2as of 14 Oct, 3:31 PM IST|USD / INR₹95.140%H ₹95.27 · L ₹94.74as of 3:05 AM IST|Gold Intl (10g)₹1,27,286.671.3%H ₹1,27,482.43 · L ₹1,26,050.9upd. 6:26 AM IST|Silver Intl (1kg)₹1,71,890.380.57%H ₹1,72,272.73 · L ₹1,70,131.55upd. 6:26 AM IST|Crude WTI₹8,991.680.61%H ₹9,067.79 · L ₹8,982.17upd. 6:26 AM IST|Bitcoin₹78,55,7000.75%H ₹78,85,167.77 · L ₹78,26,232.23as of 14 Oct, 6:46 PM IST|Ethereum₹2,35,0291.22%H ₹2,36,466.39 · L ₹2,33,591.61as of 14 Oct, 6:46 PM IST|
0%
real-estate

Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat

Arth Vani DeskPublished: 2 min read
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat

Source: ET Real Estate

Arth Insight · What this means for your wallet

Immediate action
Patients considering or having undergone stent procedures should note that the government is actively working to enhance safety and regulatory oversight of coronary stents in India.
  • The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
  • Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
  • The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.

Key Highlights
  • ▸The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
  • ▸Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
  • ▸The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
  • ▸Improved patient follow-up and monitoring of complications are also key aspects being addressed.
Key Takeaways
  • ✓The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
  • ✓Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
  • ✓The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
  • ✓Improved patient follow-up and monitoring of complications are also key aspects being addressed.

In a significant move aimed at enhancing patient safety and medical device regulation, the Cabinet Secretariat has instructed the Union Health Ministry to conduct a thorough examination of safety issues related to coronary stents. This directive comes in response to specific concerns articulated by Rajya Sabha member Ajeet Madhavrao Gopchade.

MP Raises Alarm Over Stent Safety

Mr. Gopchade drew attention to particular coronary stent models that have reportedly been withdrawn from the market in Sri Lanka due to safety issues. His representation to the authorities underscored the urgent need for India to bolster its existing regulatory framework governing these critical medical devices. Coronary stents are small, expandable tubes used to open narrowed or blocked arteries in the heart, a common procedure for patients suffering from coronary artery disease.

Key Demands for Regulatory Improvement

During his address, the Rajya Sabha member outlined several crucial areas requiring immediate attention to safeguard patient well-being. These include:

  • Strengthening India's Regulatory Framework: A robust regulatory system is vital to ensure that all medical devices, especially high-risk ones like coronary stents, meet stringent safety and quality standards before and after they are used in patients. This could involve more rigorous testing, clearer approval processes, and stricter post-market surveillance.
  • Improved Clinical Documentation: Better record-keeping of clinical procedures involving stent implantation is essential. Comprehensive documentation helps track the device's performance, patient outcomes, and any complications that may arise, allowing for faster identification of issues.
  • Robust Traceability for Implanted Stents: Establishing a strong system to trace every implanted stent from its manufacturing point to the specific patient allows for swift recalls if a batch is found to be faulty. It also ensures accountability and facilitates targeted patient follow-ups.
  • Importance of Patient Follow-up: Regular monitoring of patients who have received stent implants is critical. This ensures that any device-related complications are detected early and managed effectively, improving long-term patient health.
  • Monitoring of Device-Related Complications: A systematic approach to track and analyze all complications linked to coronary stents is necessary. This data is invaluable for identifying trends, improving device design, and refining clinical practices.

What This Means for Patients

The Cabinet Secretariat's directive signals a serious commitment from the government to address public health concerns regarding medical devices. For Indian retail readers and patients, this could translate into greater confidence in the safety and quality of coronary stents used in the country. A more rigorous regulatory environment, coupled with better traceability and patient follow-up, has the potential to significantly enhance patient safety and outcomes for a procedure that affects thousands of lives annually.

The Union Health Ministry's examination is expected to delve into the specifics of the concerns raised and propose concrete measures to strengthen the oversight and safety protocols for coronary stents across India.

This report is for informational purposes only and does not constitute medical or investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
14.3%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.1%
3Y CAGR
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
10.6%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
10.1%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
10.0%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
8.8%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

Why has the Union Health Ministry been asked to examine coronary stent safety?

The Cabinet Secretariat directed the ministry to investigate safety issues after Rajya Sabha member Ajeet Madhavrao Gopchade highlighted concerns, particularly regarding certain stent models withdrawn in Sri Lanka.

What specific improvements is the government looking to implement for coronary stents?

The government aims to strengthen India's regulatory framework for coronary stents, improve clinical documentation, establish robust traceability for implanted stents, enhance patient follow-up, and better monitor device-related complications.

Who raised the initial concerns about coronary stent safety in India?

Rajya Sabha member Ajeet Madhavrao Gopchade brought these safety concerns to the attention of the authorities, leading to the Cabinet Secretariat's directive.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
real-estate

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement

Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.

6m ago·1 min readListen
Hospitals, Clinics May Soon Prominently Display Service Rates
Breaking
real-estate

Hospitals, Clinics May Soon Prominently Display Service Rates

Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.

1d ago·2 min readListen
BR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
Breaking
real-estate

BR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence

NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.

1d ago·1 min readListen
Government Panel Finalises 30% Trade Margin Cap on Cancer Drugs; ₹2,500 Crore Annual Savings Expected
Breaking
real-estate

Government Panel Finalises 30% Trade Margin Cap on Cancer Drugs; ₹2,500 Crore Annual Savings Expected

An expert group is finalizing a list of cancer medicines that will be subject to a new 30% trade margin cap. This government initiative aims to significantly reduce the cost of anti-cancer drugs, potentially saving Indian patients ₹2,500 crore annually and leading to retail price drops of up to 70% on some medicines.

2d ago·1 min readListen